...
首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB).
【24h】

Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB).

机译:无关供体造血干细胞移植(HSCT)后的慢性移植物抗宿主病(cGVHD):无关供体(URD)脐带血(UCB)受体的应答率更高。

获取原文
获取原文并翻译 | 示例
           

摘要

We present a comparative analysis of clinical presentation and response to treatment in 170 patients with chronic graft versus host disease (cGVHD) (123 following transplant from an unrelated donor [URD] and 47 from umbilical cord blood [UCB]). URD transplant recipients were significantly younger (median age 25 versus 39 years, P = .002; and the donor grafts were mostly HLA matched (67% versus 10%, P < .0001). UCB recipients had more frequent responses (complete remission [CR] + partial remission [PR]) to treatment (URD 48% versus UCB 74% at 2 months [P = .005]; 49% versus 78% at 6 months [P = .001] and 51% versus 72% at 1 year [P = .03] in the URD and UCB groups, respectively). Nonrelapse mortality (NRM) after diagnosis of cGVHD was worse after URD grafts. (1 year NRM 27% [19%-35%] URD versus 11% [2%-20%] UCB, P = .055). Separate multivariate analyses were performed in each cohort. In both, thrombocytopenia and no CR or PR at 2 months were independently associated with increased mortality. In addition, progressive onset of cGVHD was a significant predictor of increased mortality in URD cohort. These data suggest that cGVHD following UCB transplant may be more responsive to therapy and also lead to a lower NRM.
机译:我们提供了对170例慢性移植物抗宿主病(cGVHD)患者的临床表现和对治疗反应的比较分析(不相关供体[URD]移植后123例,脐带血[UCB]移植后47例)。 URD移植接受者明显年轻(中位年龄25岁vs 39岁,P = 0.002;供体移植物大多数与HLA匹配(67%vs 10%,P <.0001)。UCB接受者的反应更加频繁(完全缓解[ CR] +部分缓解[PR])至治疗(2个月时,URD 48%vs UCB 74%[P = .005]; 6个月时49%vs 78%[P = .001]; 51%vs 72%。 URD和UCB组分别为1年[P = .03]。URD移植后诊断cGVHD后的非复发死亡率(NRM)较差(1年NRM 27%[19%-35%] URD对11% [2%-20%] UCB,P = .055)在每个队列中均进行了独立的多变量分析,血小板减少和2个月无CR或PR均与死亡率增加相关;此外,cGVHD进行性发作这是URD人群死亡率增加的重要预测指标,这些数据表明UCB移植后cGVHD对治疗的反应可能更高,并且导致NRM降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号